GLP-1 vs Other Weight Loss Options: Clinical Comparison
You have probably searched for alternatives. Maybe you have seen ads for berberine as a “natural GLP-1 alternative” or heard that phentermine might cost less. You have likely wondered whether diet and exercise alone could work, or whether bariatric surgery is a better option. When you are weighing something as significant as a weight loss medication, comparing your options is the right call.
This page walks you through how GLP-1 medications compare with the main alternatives, using numbers from published studies and FDA labels rather than marketing claims. It also says where the comparisons are weak, because most of these options have never been tested against each other directly.
OTC supplements marketed as GLP-1 alternatives
The supplement industry has used GLP-1 popularity to market berberine, fiber products, and other ingredients as “natural alternatives” to prescription weight loss medications. Here is what you need to know.
No supplement activates GLP-1 receptors the way prescription GLP-1 medications do. Berberine is a plant compound whose proposed effects run mainly through other pathways, such as AMPK, an enzyme involved in how cells use energy[1]. In a 2026 meta-analysis of 23 randomized trials, berberine reduced body weight by an average of 0.88 kg (about 2 pounds) more than control groups, and the authors called for better reporting of product purity and potency[1]. A 2023 meta-analysis found modest reductions in fasting glucose and HbA1c[2]. For comparison, in the STEP 1 trial, average body weight change was -14.9% with semaglutide 2.4mg versus -2.4% with placebo over 68 weeks[3]. The designs differ, so these are not head-to-head results.
Dietary supplements are not FDA-approved to treat obesity or any other condition. If you are looking at supplements because a prescription feels out of reach, it is fair to know that the evidence for them is small, and that some, including berberine, can affect blood sugar or other medicines you take. Tell your provider about any supplement you use.
Learn more: Berberine vs GLP-1, GLP-1 Supplements vs Prescription Medications, and OTC supplements marketed as GLP-1 alternatives.
Phentermine and older weight loss medications
Phentermine is a stimulant appetite suppressant, a Schedule IV controlled substance, and widely sold as a generic. Its FDA label approves it only as short-term (“a few weeks”) monotherapy alongside a weight-reduction program. The label summarizes the trials of its drug class this way: people on these drugs lost more than people on placebo, but the extra loss was “only a fraction of a pound a week,” and the studies lasted only a few weeks[4]. It should not be used by people with a history of cardiovascular disease, hyperthyroidism, glaucoma, agitated states, or drug abuse, during pregnancy or nursing, or with MAO inhibitors[4].
Other older medications are labeled for long-term use. Their FDA labels report these results from about one year of treatment, each against placebo in its own trial:
- Phentermine and topiramate extended-release (Qsymia): -10.9% on the highest dose versus -1.6% on placebo at one year, in adults with a BMI of 35 or higher. It is a Schedule IV controlled substance, can cause birth defects, and is available only through a restricted safety program[5].
- Naltrexone and bupropion extended-release (Contrave): -5.4% versus -1.3% on placebo at 56 weeks. It carries a boxed warning about suicidal thoughts and behaviors[6].
- Liraglutide 3mg (Saxenda), an older once-daily GLP-1: -7.4% versus -3.0% on placebo at 56 weeks. It carries a boxed warning about thyroid C-cell tumors[7].
These label trials enrolled different people over different lengths of time than the newer GLP-1 trials, so set the numbers side by side with care. If you are considering an older medication because it may cost less, ask a licensed provider how each option fits your health history, and compare the total cost of each path.
Learn more: Semaglutide vs Phentermine and lower-cost paths to weight loss medication.
Bariatric surgery
No randomized trial has compared bariatric surgery with GLP-1 medication head to head (PubMed search, October 16, 2026). What exists are separate studies.
In a study of 65,093 US adults with a BMI of 35 or higher, average total weight loss was 31.2% at one year and 25.5% at five years after gastric bypass, and 25.2% at one year and 18.8% at five years after sleeve gastrectomy[8]. That is more than the average losses in the GLP-1 drug trials, but the surgery figures come from an observational study and the drug figures from placebo-controlled trials, so the gap is a general picture, not a measured difference.
The two differ in kind. Surgery is permanent or close to it: sleeve gastrectomy cannot be reversed, and gastric bypass is difficult to reverse[9]. In the same US study, 30-day rates of major adverse events were 5.0% after gastric bypass and 2.6% after sleeve gastrectomy[8], and people who have surgery need prescribed vitamin and mineral supplements and long-term follow-up[9]. GLP-1 medication carries no surgical risk and can be adjusted or stopped, though weight often returns after stopping[10] and the medications have their own risks (see below).
Under the 2022 guideline from the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), surgery is recommended for adults with a BMI of 35 or higher and should be considered for people with metabolic disease and a BMI of 30 to 34.9[11]. A licensed provider or surgical team can help you weigh both options.
Learn more: GLP-1 vs Bariatric Surgery.
Diet and exercise alone
Lifestyle programs produce real weight loss and improve health. In the Diabetes Prevention Program, a lifestyle program aimed at 7% weight loss and 150 minutes of activity a week reduced the incidence of type 2 diabetes by 58% compared with placebo over an average of 2.8 years[12]. In the Look AHEAD trial of adults with type 2 diabetes, the intensive lifestyle group lost an average of 8.6% at one year and 6.0% at study end, after a median of 9.6 years, compared with 0.7% and 3.5% in the comparison group[13].
In the GLP-1 trials, everyone received lifestyle support. In STEP 1, average weight change was -14.9% with semaglutide 2.4mg and -2.4% with placebo at 68 weeks[3]. In SURMOUNT-1, it was -15.0%, -19.5%, and -20.9% with tirzepatide 5mg, 10mg, and 15mg and -3.1% with placebo at 72 weeks[14]. These trials studied the brand-name medicines, not compounded versions. Results vary, and trial results describe study participants, not a prediction for any individual.
GLP-1 medications do not replace diet and exercise. Their labels describe use together with a reduced-calorie diet and increased physical activity[15][16]. If you have tried lifestyle changes for years and your body keeps pulling the weight back, that is not a character flaw. After weight loss, appetite hormones shift in ways that push hunger up, and in one study those changes were still present a year later[17].
Learn more: GLP-1 vs Diet and Exercise.
Comparing outcomes at a glance
Read this table with one caution: apart from SURMOUNT-5, none of these options has been compared with another in a head-to-head trial. Each row comes from a different study, with different participants, lengths, and designs, so the rows are not a ranking.
| Approach | What the published evidence shows | Type of evidence | FDA status |
|---|---|---|---|
| Berberine | 0.88 kg more weight loss than control on average[1] | Meta-analysis of 23 trials | Dietary supplement; not approved to treat any condition |
| Phentermine | “A fraction of a pound a week” more than placebo[4] | Short trials of its drug class, a few weeks long | Approved for short-term use only |
| Lifestyle program (Look AHEAD) | -8.6% at 1 year; -6.0% at about 9.6 years[13] | Randomized trial, adults with type 2 diabetes | Not applicable |
| Older long-term medications (Qsymia, Contrave, Saxenda) | -5.4% to -10.9% vs -1.3% to -3.0% placebo at about 1 year[5][6][7] | Label trials | FDA-approved |
| Semaglutide 2.4mg (STEP 1) | -14.9% vs -2.4% placebo at 68 weeks[3] | Randomized, placebo-controlled trial | FDA-approved as Wegovy |
| Tirzepatide 15mg (SURMOUNT-1) | -20.9% vs -3.1% placebo at 72 weeks[14] | Randomized, placebo-controlled trial | FDA-approved as Zepbound |
| Bariatric surgery | -25.2% (sleeve) to -31.2% (bypass) at 1 year[8] | Observational study of surgery patients | Surgical procedure |
In SURMOUNT-5, the only head-to-head trial of the two newest medications, 751 adults took the highest dose they tolerated of tirzepatide or semaglutide for 72 weeks; average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide[18]. The trial was open-label.
Results vary. Trial results describe study participants and are not a prediction for any individual. Transformation Health does not accept payment from providers. How we make money.
Risks to weigh alongside the benefits
The Wegovy and Zepbound labels carry a boxed warning about thyroid C-cell tumors seen in rodents; it is unknown whether either medication causes these tumors, including medullary thyroid carcinoma, in humans. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or by people with a known serious allergy to the medication. Both labels warn about acute pancreatitis, gallbladder disease, low blood sugar when used with insulin or sulfonylureas, kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, and the risk of inhaling stomach contents during anesthesia or deep sedation. The most common side effects are gastrointestinal, such as nausea, diarrhea, vomiting, constipation, and abdominal pain[15][16].
Weight often returns after stopping. In SURMOUNT-4, adults who switched from tirzepatide to placebo regained an average of 14.0% of body weight over the next 52 weeks, while those who continued lost a further 5.5%[10].
How to think about your options
Your choice depends on your situation, not on which approach produced the biggest number in a separate study.
A few questions can help you sort it out:
- What have you already tried, and what happened? If lifestyle changes alone have not held, that is common and has a biological basis, and it is worth telling a provider.
- How long do you expect to need treatment? Phentermine is labeled for a few weeks; GLP-1 medications and the other older medications are labeled for long-term use, and weight often returns when they stop.
- How do you feel about surgery? Surgery is permanent or close to it, has its own eligibility thresholds, and needs long-term follow-up.
- What risks matter most to you? Each option has its own label warnings, from controlled-substance status to boxed warnings.
- What will it cost in total? Prices vary by program, pharmacy, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
A licensed provider can review your health history, goals, and previous attempts with you. That conversation should include all of your options.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedSources
[1] Elahi Vahed I, Shahir-Roudi E, Nojumi S, et al. “The effect of berberine on obesity indices: a systematic review and meta-analysis.” Int J Obes (Lond). 2026;50(1):53-73. https://pubmed.ncbi.nlm.nih.gov/41310257/ (23 randomized trials; body weight mean difference -0.88 kg versus control; call for better purity and potency reporting.)
[2] Zhao JV, Huang X, Zhang J, et al. “Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.” J Nutr. 2023;153(10):2939-2950. https://pubmed.ncbi.nlm.nih.gov/37598753/ (Reductions in fasting glucose and HbA1c.)
[3] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ (STEP 1: 1,961 adults without diabetes; -14.9% vs -2.4% at 68 weeks, both with lifestyle intervention.)
[4] U.S. Food and Drug Administration. ADIPEX-P (phentermine hydrochloride) tablets and capsules, prescribing information. Revised 01/2012 (the most recent label posted on Drugs@FDA as of 2026-10-16). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf (Short-term monotherapy indication, Schedule IV status, class efficacy summary, contraindications.)
[5] U.S. Food and Drug Administration. QSYMIA (phentermine and topiramate extended-release capsules), prescribing information. Revised 03/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022580s032lbl.pdf (Study 1 results, Schedule IV status, embryo-fetal toxicity, REMS.)
[6] U.S. Food and Drug Administration. CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, prescribing information. Revised 11/2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/200063s024s026lbl.pdf (COR-I results, boxed warning.)
[7] U.S. Food and Drug Administration. SAXENDA (liraglutide) injection, prescribing information. Revised 02/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321Orig1s024lbl.pdf (Study 1 results, boxed warning.)
[8] Arterburn D, Wellman R, Emiliano A, et al. “Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study.” Ann Intern Med. 2018;169(11):741-750. https://pubmed.ncbi.nlm.nih.gov/30383139/ (65,093 US adults; total weight loss at 1 and 5 years; 30-day major adverse events; observational design.)
[9] National Institute of Diabetes and Digestive and Kidney Diseases. “Bariatric Surgery.” Last reviewed September 2020. https://www.niddk.nih.gov/health-information/weight-management/bariatric-surgery (Reversibility, supplements and follow-up after surgery. Accessed 2026-10-16.)
[10] Aronne LJ, Sattar N, Horn DB, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/ (Regain of 14.0% after switching to placebo vs a further 5.5% loss with continued treatment.)
[11] Eisenberg D, Shikora SA, Aarts E, et al. “2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery.” Obes Surg. 2023;33(1):3-14. https://pubmed.ncbi.nlm.nih.gov/36336720/ (BMI thresholds.)
[12] Knowler WC, Barrett-Connor E, Fowler SE, et al. “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.” N Engl J Med. 2002;346(6):393-403. https://pubmed.ncbi.nlm.nih.gov/11832527/ (7% weight-loss goal, 150 minutes of activity, 58% reduction in diabetes incidence, 2.8-year average follow-up.)
[13] Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL, et al. “Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes.” N Engl J Med. 2013;369(2):145-154. https://pubmed.ncbi.nlm.nih.gov/23796131/ (8.6% vs 0.7% weight loss at 1 year; 6.0% vs 3.5% at study end; median follow-up 9.6 years.)
[14] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/ (SURMOUNT-1: 2,539 adults without diabetes; -15.0%, -19.5%, -20.9% vs -3.1% at 72 weeks.)
[15] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Indication with diet and activity, boxed warning, contraindications, warnings, most common adverse reactions.)
[16] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Indication with diet and activity, boxed warning, contraindications, warnings, most common adverse reactions.)
[17] Sumithran P, Prendergast LA, Delbridge E, et al. “Long-Term Persistence of Hormonal Adaptations to Weight Loss.” N Engl J Med. 2011;365(17):1597-1604. https://pubmed.ncbi.nlm.nih.gov/22029981/ (Changes in appetite hormones and hunger after weight loss, persisting at one year.)
[18] Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/ (SURMOUNT-5: 751 adults, open-label; 20.2% vs 13.7% at 72 weeks.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Clinical trial and label data on this page apply to the FDA-approved products studied. Results vary. Trial results describe study participants and are not a prediction for any individual. Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Dietary supplements are not FDA-approved to treat any condition. Wegovy and Saxenda are trademarks of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Qsymia, Contrave, and Adipex-P are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by any of these companies. Transformation Health does not accept payment from providers. How we make money.